Abstract
Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have